BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 38621830)

  • 1. Harnessing Antitumor Immunity in Ovarian Cancer.
    Kurnit KC; Odunsi K
    Cold Spring Harb Perspect Med; 2024 Apr; ():. PubMed ID: 38621830
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Deciphering tumor immune microenvironment differences between high-grade serous and endometrioid ovarian cancer to investigate their potential in indicating immunotherapy response.
    Yang H; Gu X; Fan R; Zhu Q; Zhong S; Wan X; Chen Q; Zhu L; Feng F
    J Ovarian Res; 2023 Nov; 16(1):223. PubMed ID: 37993916
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New Approaches for Immune Directed Treatment for Ovarian Cancer.
    Hardwick N; Frankel PH; Cristea M
    Curr Treat Options Oncol; 2016 Mar; 17(3):14. PubMed ID: 26942589
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combined PD-1/PD-L1 and tumor-infiltrating immune cells redefined a unique molecular subtype of high-grade serous ovarian carcinoma.
    Liu P; Chen R; Zhang X; Fu R; Tao L; Jia W
    BMC Genomics; 2022 Jan; 23(1):51. PubMed ID: 35026984
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunotherapy in ovarian cancer.
    Odunsi K
    Ann Oncol; 2017 Nov; 28(suppl_8):viii1-viii7. PubMed ID: 29232467
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antigen-specific active immunotherapy for ovarian cancer.
    Paijens ST; Leffers N; Daemen T; Helfrich W; Boezen HM; Cohlen BJ; Melief CJ; de Bruyn M; Nijman HW
    Cochrane Database Syst Rev; 2018 Sep; 9(9):CD007287. PubMed ID: 30199097
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development and Characterization of a Luciferase Labeled, Syngeneic Murine Model of Ovarian Cancer.
    Russell S; Lim F; Peters PN; Wardell SE; Whitaker R; Chang CY; Previs RA; McDonnell DP
    Cancers (Basel); 2022 Aug; 14(17):. PubMed ID: 36077756
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Attenuation of Sialylation Augments Antitumor Immunity and Improves Response to Immunotherapy in Ovarian Cancer.
    Cao K; Zhang G; Yang M; Wang Y; He M; Zhang C; Huang Y; Lu J; Liu H
    Cancer Res; 2023 Jul; 83(13):2171-2186. PubMed ID: 37172314
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Integration of local and systemic immunity in ovarian cancer: Implications for immunotherapy.
    Rajtak A; Ostrowska-Leśko M; Żak K; Tarkowski R; Kotarski J; Okła K
    Front Immunol; 2022; 13():1018256. PubMed ID: 36439144
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunotherapy for ovarian cancer: recent advances and perspectives.
    Zsiros E; Tanyi J; Balint K; Kandalaft LE
    Curr Opin Oncol; 2014 Sep; 26(5):492-500. PubMed ID: 25036883
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combination therapy targeting both innate and adaptive immunity improves survival in a pre-clinical model of ovarian cancer.
    Hartl CA; Bertschi A; Puerto RB; Andresen C; Cheney EM; Mittendorf EA; Guerriero JL; Goldberg MS
    J Immunother Cancer; 2019 Jul; 7(1):199. PubMed ID: 31362778
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neoadjuvant Chemotherapy of Ovarian Cancer Results in Three Patterns of Tumor-Infiltrating Lymphocyte Response with Distinct Implications for Immunotherapy.
    Lo CS; Sanii S; Kroeger DR; Milne K; Talhouk A; Chiu DS; Rahimi K; Shaw PA; Clarke BA; Nelson BH
    Clin Cancer Res; 2017 Feb; 23(4):925-934. PubMed ID: 27601594
    [No Abstract]   [Full Text] [Related]  

  • 13. CDK4/6 inhibition promotes immune infiltration in ovarian cancer and synergizes with PD-1 blockade in a B cell-dependent manner.
    Zhang QF; Li J; Jiang K; Wang R; Ge JL; Yang H; Liu SJ; Jia LT; Wang L; Chen BL
    Theranostics; 2020; 10(23):10619-10633. PubMed ID: 32929370
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The immunotherapy of patients with ovarian cancer.
    Hwu P; Freedman RS
    J Immunother; 2002; 25(3):189-201. PubMed ID: 12000860
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunity and immune suppression in human ovarian cancer.
    Preston CC; Goode EL; Hartmann LC; Kalli KR; Knutson KL
    Immunotherapy; 2011 Apr; 3(4):539-56. PubMed ID: 21463194
    [TBL] [Abstract][Full Text] [Related]  

  • 16. STING pathway expression in low-grade serous carcinoma of the ovary: an unexpected therapeutic opportunity?
    Huvila J; Cochrane DR; Ta M; Chow C; Greening K; Leung S; Karnezis AN; DiFeo A; Huntsman DG
    J Pathol Clin Res; 2021 Nov; 7(6):548-555. PubMed ID: 34138519
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Harnessing Pyroptosis for Cancer Immunotherapy.
    Bourne CM; Taabazuing CY
    Cells; 2024 Feb; 13(4):. PubMed ID: 38391959
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vascular normalization: reshaping the tumor microenvironment and augmenting antitumor immunity for ovarian cancer.
    Yu P; Wang Y; Yuan D; Sun Y; Qin S; Li T
    Front Immunol; 2023; 14():1276694. PubMed ID: 37936692
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Regulation of Ovarian Cancer Prognosis by Immune Cells in the Tumor Microenvironment.
    Drakes ML; Stiff PJ
    Cancers (Basel); 2018 Sep; 10(9):. PubMed ID: 30200478
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical significance of the immune microenvironment in ovarian cancer patients.
    Yang L; Wang S; Zhang Q; Pan Y; Lv Y; Chen X; Zuo Y; Hao D
    Mol Omics; 2018 Oct; 14(5):341-351. PubMed ID: 30129640
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.